CS277030B6 - Antiviral and antibacterial agent - Google Patents
Antiviral and antibacterial agent Download PDFInfo
- Publication number
- CS277030B6 CS277030B6 CS893180A CS318089A CS277030B6 CS 277030 B6 CS277030 B6 CS 277030B6 CS 893180 A CS893180 A CS 893180A CS 318089 A CS318089 A CS 318089A CS 277030 B6 CS277030 B6 CS 277030B6
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- dimer
- lysozyme
- ribonuclease
- composition
- composition according
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 11
- 239000003242 anti bacterial agent Substances 0.000 title claims description 7
- 239000003443 antiviral agent Substances 0.000 title claims description 5
- 102000016943 Muramidase Human genes 0.000 claims abstract description 99
- 108010014251 Muramidase Proteins 0.000 claims abstract description 99
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims abstract description 99
- 229960000274 lysozyme Drugs 0.000 claims abstract description 99
- 239000004325 lysozyme Substances 0.000 claims abstract description 99
- 235000010335 lysozyme Nutrition 0.000 claims abstract description 99
- 239000000203 mixture Substances 0.000 claims abstract description 61
- 239000003937 drug carrier Substances 0.000 claims abstract description 7
- 239000000539 dimer Substances 0.000 claims description 115
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 claims description 27
- 102000005891 Pancreatic ribonuclease Human genes 0.000 claims description 27
- 239000002674 ointment Substances 0.000 claims description 17
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 108010015937 ribonuclease dimer Proteins 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 239000000829 suppository Substances 0.000 claims description 5
- 239000012266 salt solution Substances 0.000 claims description 4
- 239000012188 paraffin wax Substances 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 abstract description 27
- 108090000790 Enzymes Proteins 0.000 abstract description 27
- 229940088598 enzyme Drugs 0.000 abstract description 27
- 230000001472 cytotoxic effect Effects 0.000 abstract description 25
- 231100000433 cytotoxic Toxicity 0.000 abstract description 24
- 102000006382 Ribonucleases Human genes 0.000 abstract description 23
- 108010083644 Ribonucleases Proteins 0.000 abstract description 23
- 238000000034 method Methods 0.000 abstract description 9
- 241000282414 Homo sapiens Species 0.000 abstract description 6
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 6
- 208000031295 Animal disease Diseases 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 38
- 201000010099 disease Diseases 0.000 description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 32
- 238000012360 testing method Methods 0.000 description 22
- 239000000178 monomer Substances 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 241000282472 Canis lupus familiaris Species 0.000 description 18
- 210000002950 fibroblast Anatomy 0.000 description 18
- 230000001580 bacterial effect Effects 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 14
- 235000013601 eggs Nutrition 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 11
- 230000003013 cytotoxicity Effects 0.000 description 11
- 231100000135 cytotoxicity Toxicity 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 10
- 241000283690 Bos taurus Species 0.000 description 9
- 230000035931 haemagglutination Effects 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 241000711408 Murine respirovirus Species 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 239000008267 milk Substances 0.000 description 8
- 235000013336 milk Nutrition 0.000 description 8
- 210000004080 milk Anatomy 0.000 description 8
- 241000194017 Streptococcus Species 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 208000004396 mastitis Diseases 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 208000001688 Herpes Genitalis Diseases 0.000 description 4
- 208000005141 Otitis Diseases 0.000 description 4
- 241000191940 Staphylococcus Species 0.000 description 4
- 206010042674 Swelling Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 210000003717 douglas' pouch Anatomy 0.000 description 4
- 201000004946 genital herpes Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 231100001231 less toxic Toxicity 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 208000007514 Herpes zoster Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 208000019258 ear infection Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000004392 genitalia Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 231100000065 noncytotoxic Toxicity 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000701931 Canine parvovirus Species 0.000 description 2
- 241000867607 Chlorocebus sabaeus Species 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001013832 Homo sapiens Mitochondrial peptide methionine sulfoxide reductase Proteins 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 102100031767 Mitochondrial peptide methionine sulfoxide reductase Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000008071 Parvoviridae Infections Diseases 0.000 description 2
- 206010057343 Parvovirus infection Diseases 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 241000588767 Proteus vulgaris Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000193985 Streptococcus agalactiae Species 0.000 description 2
- 241000194042 Streptococcus dysgalactiae Species 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- 201000008100 Vaginitis Diseases 0.000 description 2
- 208000000558 Varicose Ulcer Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000003512 furunculosis Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940007042 proteus vulgaris Drugs 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 208000015898 Bacterial Skin disease Diseases 0.000 description 1
- 206010004142 Bartholinitis Diseases 0.000 description 1
- 208000031462 Bovine Mastitis Diseases 0.000 description 1
- 241000224483 Coccidia Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000022555 Genital disease Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010024561 Lip pain Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- MNLRQHMNZILYPY-MDMHTWEWSA-N N-acetyl-alpha-D-muramic acid Chemical compound OC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@@H]1NC(C)=O MNLRQHMNZILYPY-MDMHTWEWSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 206010042731 Sycosis barbae Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 208000032159 Vaginal inflammation Diseases 0.000 description 1
- 208000012544 Viral Skin disease Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 210000002947 bartholin's gland Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000009200 cobalt therapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003532 endogenous pyrogen Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000002122 leukaemogenic effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000011542 limb amputation Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229940115920 streptococcus dysgalactiae Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17858888A | 1988-05-26 | 1988-05-26 | |
| PCT/US1988/001785 WO1989011294A1 (en) | 1988-05-26 | 1988-05-26 | Antiviral or antibacterial compound and method of use |
| OA59731A OA09785A (en) | 1988-05-26 | 1990-01-26 | Antiviral or antibacterial compound and method of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CS318089A3 CS318089A3 (en) | 1992-05-13 |
| CS277030B6 true CS277030B6 (en) | 1992-11-18 |
Family
ID=33162813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS893180A CS277030B6 (en) | 1988-05-26 | 1989-05-26 | Antiviral and antibacterial agent |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US5200182A (hu) |
| EP (1) | EP0380484B1 (hu) |
| JP (1) | JPH0649659B2 (hu) |
| AT (1) | ATE93143T1 (hu) |
| AU (1) | AU624331B2 (hu) |
| BG (1) | BG60544B1 (hu) |
| CA (1) | CA1335425C (hu) |
| CS (1) | CS277030B6 (hu) |
| DK (1) | DK173078B1 (hu) |
| ES (1) | ES2011577A6 (hu) |
| FI (1) | FI900412A0 (hu) |
| HK (1) | HK42394A (hu) |
| HU (1) | HU204710B (hu) |
| IL (1) | IL90092A (hu) |
| LV (1) | LV10054B (hu) |
| MA (1) | MA21560A1 (hu) |
| MW (1) | MW390A1 (hu) |
| OA (1) | OA09785A (hu) |
| PH (1) | PH26284A (hu) |
| RU (1) | RU2092183C1 (hu) |
| WO (1) | WO1989011294A1 (hu) |
| YU (1) | YU109289A (hu) |
| ZA (1) | ZA893382B (hu) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0649659B2 (ja) * | 1988-05-26 | 1994-06-29 | ニカヘルス プロダクツ，リミテッド | 抗ウイルス及び抗菌組成物並びに使用方法 |
| BR9007970A (pt) * | 1990-01-08 | 1992-11-17 | Nika Health Products Ltd | Processo para preparacao de dimeros de ribonuclease |
| US5989880A (en) * | 1990-01-08 | 1999-11-23 | Nika Health Products Ltd. | Method of preparing lysozyme dimers |
| PL173978B1 (pl) * | 1992-07-13 | 1998-05-29 | Nika Health Products Ltd | Sposób oddziaływania na wydzielanie cytokin w hodowli limfocytów krwi obwodowej |
| CH682541A5 (de) * | 1992-06-23 | 1993-10-15 | Urs Viktor Dr Wirth | Biochemische Inaktivierung von RNA-Viren. |
| US6183742B1 (en) | 1992-07-13 | 2001-02-06 | Nika Health Products, Limited | Applications of lysozyme dimer |
| DZ1964A1 (fr) * | 1995-01-13 | 2002-10-15 | Nika Health Products Ltd | Nouvelle applications d'un dimère de lysozyme. |
| GB2304048A (en) * | 1995-08-12 | 1997-03-12 | John William Carson | Medicament containing saliva extract |
| US6123937A (en) * | 1997-03-14 | 2000-09-26 | Nika Health Products, Limited | Applications of lysozyme dimer |
| US7338936B2 (en) * | 2000-11-28 | 2008-03-04 | House Ear Institute | Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis |
| US6716813B2 (en) * | 2000-11-28 | 2004-04-06 | House Ear Institute | Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis |
| JP2002187853A (ja) * | 2000-12-21 | 2002-07-05 | Shinei Ferumentekku:Kk | 動物の乳頭除菌剤および菌環境改善方法 |
| DE10210285A1 (de) * | 2002-03-08 | 2003-11-13 | Medigene Ag | Reversibles Toxin und seine Verwendung |
| US8470315B2 (en) * | 2004-04-13 | 2013-06-25 | Quintessence Biosciences, Inc. | Non-natural ribonuclease conjugates as cytotoxic agents |
| US20050244402A1 (en) * | 2004-04-30 | 2005-11-03 | Villanueva Julie M | Absorption of pain-causing agents |
| US7348301B2 (en) * | 2006-02-16 | 2008-03-25 | Buckman Laboratories International, Inc. | Lysozyme-based method and composition to control the growth of microorganisms in aqueous systems |
| JP2009541333A (ja) * | 2006-06-23 | 2009-11-26 | クインテセンス バイオサイエンシーズ インコーポレーティッド | 修飾リボヌクレアーゼ |
| EP2049151A4 (en) | 2006-07-17 | 2010-03-24 | Quintessence Biosciences Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER |
| WO2008109401A2 (en) * | 2007-03-02 | 2008-09-12 | Saint Simeon Lda | Composition and method for treating papilloma virus and equine sarcoids |
| WO2009036000A2 (en) * | 2007-09-11 | 2009-03-19 | University Of Maryland, Baltimore | Methods of treating a microbial infection by modulating rnase-l expression and/or activity |
| US8697062B2 (en) * | 2007-10-08 | 2014-04-15 | Quintessence Biosciences, Inc. | Compositions and methods for ribonuclease-based therapeutics |
| JP2012504423A (ja) | 2008-10-01 | 2012-02-23 | クインテッセンス バイオサイエンシズ，インコーポレーテッド | 治療用リボヌクレアーゼ |
| US20100215707A1 (en) * | 2009-02-25 | 2010-08-26 | Mcdonald Thomas | Activated creatinine and precursors thereof as antibacterial agents, compositions and products containing such agents and uses thereof |
| NZ600269A (en) | 2009-05-20 | 2014-02-28 | Dec Int Nz Ltd | Delivery device for treatment of mastitis |
| PL2457576T3 (pl) | 2010-11-29 | 2021-04-06 | Eurochit Danuta Kruszewska | Szczep Lactobacillus reuteri do stosowania medycznego i weterynaryjnego w profilaktyce oraz w leczeniu zespołu metabolicznego lub infekcji |
| RU2548803C2 (ru) * | 2011-11-28 | 2015-04-20 | Общество с ограниченной ответственностью " Фарматренд" | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ ГЛАЗНЫХ ИНФЕКЦИЙ P. Aeruginosa, СОДЕРЖАЩАЯ РЕКОМБИНАНТНЫЙ ЛИЗОЦИМ |
| RU2509801C2 (ru) * | 2012-03-22 | 2014-03-20 | Борис Михайлович Куриненко | СПОСОБ ИСПОЛЬЗОВАНИЯ РИБОНУКЛЕАЗЫ Bacillus intermedius |
| CN104684565A (zh) | 2012-05-29 | 2015-06-03 | 达努塔·克鲁谢夫斯卡 | 在人类和兽医的预防和医疗中有用的、包含罗伊氏乳杆菌dan080的纳米产品及其医疗用途 |
| EP2674162A1 (en) | 2012-05-29 | 2013-12-18 | Danuta Kruszewska | Nanoproduct comprising lactobacillus reuteri dan080 useful in prophylaxis and medicine, both human and veterinary and medical use of the same |
| RU2504397C1 (ru) * | 2012-10-25 | 2014-01-20 | Леонид Леонидович Клопотенко | Фармацевтическая композиция, содержащая фермент рибонуклеазу и глицирризиновую кислоту или ее соли: глицирризинат аммония, или дикалия, или тринатрия |
| US9950075B2 (en) | 2013-03-15 | 2018-04-24 | The University Of Massachusetts | Compositions and methods for delivering agents to the central nervous system |
| US9573980B2 (en) | 2013-03-15 | 2017-02-21 | Spogen Biotech Inc. | Fusion proteins and methods for stimulating plant growth, protecting plants from pathogens, and immobilizing Bacillus spores on plant roots |
| JP5806434B1 (ja) | 2014-02-21 | 2015-11-10 | 国立大学法人東京海洋大学 | ノロウィルス不活化剤及びその製造方法、ノロウィルス不活化方法、ノロウィルス不活化用リゾチーム類の製造方法、ノロウィルス感染の予防薬又は治療薬、並びにノロウィルス不活化用皮膚外用剤 |
| CN106659165B (zh) * | 2014-07-31 | 2021-06-01 | 丘比株式会社 | 含水流动状组合物及其制造方法、以及溶菌酶加工品和/或其盐、及其制造方法 |
| UA126325C2 (uk) | 2014-09-17 | 2022-09-21 | Споуджен Байотек Інк. | Злитий білок, рекомбінантна бактерія і спосіб її застосування |
| LV15071B (lv) * | 2015-07-14 | 2016-02-20 | Rīgas Stradiņa Universitāte | Kompozīcija subklīniska mastīta ārstēšanai govīm |
| RU2634264C1 (ru) * | 2016-09-19 | 2017-10-24 | Александр Ливиевич Ураков | Крем-молочко для лечения опоясывающего лишая |
| CN113861760B (zh) | 2016-12-28 | 2023-05-05 | Dic株式会社 | 分散体 |
| WO2021021765A1 (en) * | 2019-07-26 | 2021-02-04 | Evolve Biosystems, Inc. | Nutritive compositions with bioactive proteins |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1268M (fr) * | 1961-06-29 | 1962-04-24 | Puiseux | Médicament antimitotique et antiviral. |
| FR4020M (hu) * | 1965-01-29 | 1966-03-21 | ||
| DE1517751C3 (de) * | 1965-07-08 | 1975-02-27 | Eisai Co., Ltd., Tokio | Verfahren zum Verhindern der Bildung von flockigen Lysozym- und/oder Lysozymsalzniederschlägen in wässrigen Lösungen, die Lysozym und/oder Lysozymsalze enthalten |
| DE1545644A1 (de) * | 1965-12-06 | 1969-08-07 | Boehringer Sohn Ingelheim | Verfahren zur Herstellung von neuen quaternaeren Scopolammoniumsalzen |
| GB1110504A (en) * | 1966-03-18 | 1968-04-18 | Prodotti Antibiotici Spa | Pharmaceutical compositions |
| US4221794A (en) * | 1979-06-21 | 1980-09-09 | Newport Pharmaceuticals International, Inc. | Method of imparting immunomodulating and antiviral activity |
| US4510144A (en) * | 1981-08-26 | 1985-04-09 | Newport Pharmaceuticals International | Methods of imparting immunomodulating activity with dihydrothiazolo purine derivatives |
| EP0187705A3 (en) * | 1985-01-08 | 1988-05-11 | Norwich Eaton Pharmaceuticals, Inc. | Imidazo(4,5-f)quinolines useful as immunomodulating agents |
| US4739046A (en) * | 1985-08-19 | 1988-04-19 | Luzio Nicholas R Di | Soluble phosphorylated glucan |
| US4744984A (en) * | 1985-10-08 | 1988-05-17 | Vetrepharm Research, Inc. | Antiviral immunotherapeutic agent and preparation thereof |
| JPH0649659B2 (ja) * | 1988-05-26 | 1994-06-29 | ニカヘルス プロダクツ，リミテッド | 抗ウイルス及び抗菌組成物並びに使用方法 |
-
1988
- 1988-05-26 JP JP63504463A patent/JPH0649659B2/ja not_active Expired - Fee Related
- 1988-05-26 AU AU19408/88A patent/AU624331B2/en not_active Expired
- 1988-05-26 RU SU884743095A patent/RU2092183C1/ru active
- 1988-05-26 HU HU883981A patent/HU204710B/hu unknown
- 1988-05-26 WO PCT/US1988/001785 patent/WO1989011294A1/en active IP Right Grant
- 1988-05-26 AT AT88905146T patent/ATE93143T1/de not_active IP Right Cessation
- 1988-05-26 US US07/459,738 patent/US5200182A/en not_active Expired - Lifetime
- 1988-05-26 EP EP88905146A patent/EP0380484B1/en not_active Expired - Lifetime
-
1989
- 1989-04-20 CA CA000597341A patent/CA1335425C/en not_active Expired - Fee Related
- 1989-04-27 IL IL9009289A patent/IL90092A/en not_active IP Right Cessation
- 1989-05-08 ZA ZA893382A patent/ZA893382B/xx unknown
- 1989-05-16 ES ES8901637A patent/ES2011577A6/es not_active Expired - Fee Related
- 1989-05-23 PH PH38684A patent/PH26284A/en unknown
- 1989-05-24 MA MA21811A patent/MA21560A1/fr unknown
- 1989-05-26 YU YU01092/89A patent/YU109289A/xx unknown
- 1989-05-26 CS CS893180A patent/CS277030B6/cs not_active IP Right Cessation
-
1990
- 1990-01-22 MW MW3/90A patent/MW390A1/xx unknown
- 1990-01-22 DK DK199000168A patent/DK173078B1/da not_active IP Right Cessation
- 1990-01-25 FI FI900412A patent/FI900412A0/fi not_active IP Right Cessation
- 1990-01-26 OA OA59731A patent/OA09785A/en unknown
- 1990-02-22 BG BG91270A patent/BG60544B1/bg unknown
-
1992
- 1992-04-08 US US07/865,002 patent/US5466449A/en not_active Expired - Lifetime
- 1992-12-28 LV LVP-92-508A patent/LV10054B/en unknown
-
1994
- 1994-05-05 HK HK42394A patent/HK42394A/xx not_active IP Right Cessation
-
1995
- 1995-06-07 US US08/474,663 patent/US6099835A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| FI900412A0 (fi) | 1990-01-25 |
| DK173078B1 (da) | 1999-12-20 |
| PH26284A (en) | 1992-04-10 |
| YU109289A (en) | 1991-08-31 |
| HU883981D0 (en) | 1990-12-28 |
| ES2011577A6 (es) | 1990-01-16 |
| EP0380484B1 (en) | 1993-08-18 |
| MW390A1 (en) | 1990-11-14 |
| HUT54060A (en) | 1991-01-28 |
| JPH03504121A (ja) | 1991-09-12 |
| LV10054A (lv) | 1994-05-10 |
| DK16890D0 (da) | 1990-01-22 |
| ZA893382B (en) | 1991-01-30 |
| JPH0649659B2 (ja) | 1994-06-29 |
| LV10054B (en) | 1995-02-20 |
| BG91270A (bg) | 1993-12-24 |
| MA21560A1 (fr) | 1989-12-31 |
| HK42394A (en) | 1994-05-13 |
| OA09785A (en) | 1994-04-15 |
| ATE93143T1 (de) | 1993-09-15 |
| IL90092A (en) | 1995-03-30 |
| BG60544B1 (en) | 1995-08-28 |
| WO1989011294A1 (en) | 1989-11-30 |
| US5200182A (en) | 1993-04-06 |
| RU2092183C1 (ru) | 1997-10-10 |
| CS318089A3 (en) | 1992-05-13 |
| US5466449A (en) | 1995-11-14 |
| AU624331B2 (en) | 1992-06-11 |
| US6099835A (en) | 2000-08-08 |
| AU1940888A (en) | 1989-12-12 |
| HU204710B (en) | 1992-02-28 |
| DK16890A (da) | 1990-01-22 |
| EP0380484A1 (en) | 1990-08-08 |
| CA1335425C (en) | 1995-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CS277030B6 (en) | Antiviral and antibacterial agent | |
| AP628A (en) | New applications of lysozyme dimer. | |
| AU677786B2 (en) | Lysozyme dimer and compositions containing the same | |
| EP0548558A2 (en) | Compositions containing surfactants as potentiating agents for the treatment of mammalian diseases | |
| US6183742B1 (en) | Applications of lysozyme dimer | |
| KR930004599B1 (ko) | 항바이러스성 또는 항균성 조성물 | |
| Powell, SJ & MacLeod | Ambilhar, a nitrothiazole derivative, in urinary tract bilharzia | |
| MXPA97005246A (en) | New applications of dimero de lisoz | |
| MXPA98009256A (en) | Antimicrobial treatment for herpes simplex virus and other infectious diseases | |
| PL176407B1 (pl) | Kompozycja farmaceutyczna zawierająca dimer lizozymu |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF00 | In force as of 2000-06-30 in czech republic | ||
| MK4A | Patent expired |
Effective date: 20090526 |